Top Health Officials Meet to Discuss Pause of Johnson & Johnson Vaccine
Cheddar News – Apr 15, 2021 12:02 am
Covid-19
Apr. 28, 2021
NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia
PR Newswire RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ — NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure. The EAP will be conducted in […]
Apr. 26, 2021
Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team
PR Newswire RADNOR, Pa., April 26, 2021 /PRNewswire/ — Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The […]
Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins
Patients with acute respiratory failure may now enroll in NIH-sponsored trial. National Institutes of Health – News Releases A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure. The trial is supported by two […]
Apr. 19, 2021
NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development
CISON PR Newswire RADNOR, Pa., April 19, 2021 /PRNewswire/ — The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx’s ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis. However, NeuroRx was obligated to disclose Relief’s nonpayment of development costs required under the signed collaboration […]
FDA Investigating Quality Issues That Led To Millions Of J&J Vaccines To Be Thrown Out
Cheddar News – Apr 2, 2021 02:23 pm
New COVID 19 Drug can Effectively Treat Patients – Discussion with Dr. Javitt, CEO NeuroRx
Interview with Dr. Yo – Streamed live on Feb 11, 2021
New COVID-19 drug used to treat patients suffering from respiratory failure is in trials
Fox Business Apr. 07, 2021 – 5:06 – NeuroRX CEO Dr. Jonathan Javitt discusses the new COVID-19 drug for respiratory distress and vaccine boosters.
Apr. 6, 2021
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
CISON PR Newswire RADNOR, Pa., April 6, 2021 /PRNewswire/ — NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed […]
